270 related articles for article (PubMed ID: 28283585)
1. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
[TBL] [Abstract][Full Text] [Related]
2. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
Uy N; Singh A; Gore SD; Prebet T
Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
[TBL] [Abstract][Full Text] [Related]
7. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.
Cogle CR; Ortendahl JD; Bentley TG; Anene AM; Megaffin S; McKearn TJ; Petrone ME; Mukherjee S
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):275-84. PubMed ID: 26589773
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y; Sekeres MA
Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
[TBL] [Abstract][Full Text] [Related]
10. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
11. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Komrokji RS
Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
[TBL] [Abstract][Full Text] [Related]
12. Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis.
Joshi N; Kale H; Corman S; Wert T; Hill K; Zeidan AM
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e248-e254. PubMed ID: 33422471
[TBL] [Abstract][Full Text] [Related]
13. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Sohn SK; Moon JH
Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
[TBL] [Abstract][Full Text] [Related]
14. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
Zeidan AM; Klink AJ; McGuire M; Feinberg B
Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
[TBL] [Abstract][Full Text] [Related]
15. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hatoum HT; Lin SJ; Buchner D; Kim E
Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
[TBL] [Abstract][Full Text] [Related]
16. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.
Patel SS; Sekeres MA; Nazha A
Leuk Lymphoma; 2017 Nov; 58(11):2532-2539. PubMed ID: 28351181
[TBL] [Abstract][Full Text] [Related]
17. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.
Zeidan AM; Hu X; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Bewersdorf JP; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
Leuk Lymphoma; 2020 Feb; 61(2):397-408. PubMed ID: 31570040
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
19. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.
Roberts DA; Steensma DP
Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600
[TBL] [Abstract][Full Text] [Related]
20. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
